Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Novan stock

Own Novan stock in just a few minutes.

Novan, Inc is a biotechnology business based in the US. Novan shares (NOVN) are listed on the NASDAQ and all prices are listed in US Dollars. Novan employs 23 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Novan

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – NOVN – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Novan share price

Use our graph to track the performance of NOVN stocks over time.

Novan shares at a glance

Information last updated 2021-04-23.
52-week range$0.31 - $2.59
50-day moving average $1.47
200-day moving average $1.05
Wall St. target price$2.83
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.96

Buy Novan shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Novan stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Novan financials

Revenue TTM $4.9 million
Gross profit TTM $-3,907,000
Return on assets TTM -42.25%
Return on equity TTM 0%
Profit margin 0%
Book value $0.02
Market capitalisation $206.2 million

TTM: trailing 12 months

Shorting Novan shares

There are currently 3.4 million Novan shares held short by investors – that's known as Novan's "short interest". This figure is 16% down from 4.1 million last month.

There are a few different ways that this level of interest in shorting Novan shares can be evaluated.

Novan's "short interest ratio" (SIR)

Novan's "short interest ratio" (SIR) is the quantity of Novan shares currently shorted divided by the average quantity of Novan shares traded daily (recently around 8.2 million). Novan's SIR currently stands at 0.42. In other words for every 100,000 Novan shares traded daily on the market, roughly 420 shares are currently held short.

However Novan's short interest can also be evaluated against the total number of Novan shares, or, against the total number of tradable Novan shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Novan's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Novan shares in existence, roughly 20 shares are currently held short) or 0.0227% of the tradable shares (for every 100,000 tradable Novan shares, roughly 23 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Novan.

Find out more about how you can short Novan stock.

Novan share dividends

We're not expecting Novan to pay a dividend over the next 12 months.

Novan share price volatility

Over the last 12 months, Novan's shares have ranged in value from as little as $0.31 up to $2.59. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Novan's is -0.0336. This would suggest that Novan's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Novan has bucked the trend.

Novan overview

Novan, Inc. , a clinical development-stage biotechnology company, provides nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases. The company also develops SB207, an anti-viral product candidate for the treatment of external genital warts; WH602, a nitric oxide-containing intravaginal gel to treat high-risk human papilloma virus (HPV); WH504, a non-gel formulation product candidate to treat high-risk HPV; and SB019 for the treatment of SARS-CoV-2. Novan, Inc. has a license agreement with Sato Pharmaceutical Co. , Ltd.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site